New agent draws a bead on colorectal cancer

Article

The FDA recently approved cetuximab (Erbitux, ImClone Systems) for use in combination with irinotecan (Camptosar, Pfizer) for the treatment of epidermal growth factor receptor-1 (EGFR-1)-expressing, metastatic CRC in patients who are refractory to irinotecan-based chemotherapy. Cetuximab was also approved for use as monotherapy for the treatment of EGFR-1-expressing, metastatic CRC in those who are intolerant of irinotecan-based chemotherapy.

Related Content
© 2024 MJH Life Sciences

All rights reserved.